Bison Capital Announces Combination with Xynomic Pharmaceuticals
by Kristi Marvin on 2018-09-13 at 9:38am

Bison Capital Acquisition Corp. (“BCAC”), announced this morning that they have signed a definitive merger agreement with Xynomic Pharmaceuticals, Inc.  Xynomic, is principally engaged in the research, development and commercialization of targeted cancer therapeutics in the U.S., Europe and China and focuses on orally delivered small molecule drugs.

Xynomic has in-licensed a clinical stage drug candidate from Pharmacyclics/AbbVie and a pre-clinical stage drug candidate from Boehringer Ingelheim.  Additionally, Xynomic is collaborating with Janssen R&D, LLC in a clinical trial of a combination therapy.

Bison Capital has not filed an investor presentation or included any financial details on Xynomic, as of yet. We will further evaluate once that’s been provided.

CONSIDERATION

The merger consideration will be payable entirely in common stock of BCAC at a value of $10.15 per share consisting of:

  • Closing consideration of $350 million in BCAC shares, and
  • Earnout consideration of an additional $100 million in BCAC shares, subject to:
    • If Xynomic obtains a worldwide exclusive license to a Phase II-ready oncology drug candidate on or prior to March 12, 2019 (to be identified)

3% of the initial BCAC shares payable to Xynomic shareholders in the merger and 3% of the earnout shares, when payable, will be held in escrow for a period of 18 months following the closing to serve as security for BCAC’s indemnity rights and any excess of the estimated closing merger consideration over the final closing merger consideration amount determined post-closing.

 

 

 

Recent Posts
by Nicholas Alan Clayton on 2023-12-11 at 10:45am

SEC Chair Gary Gensler made waves with public remarks last week noting that the agency would be looking at potentially making enforcement actions against companies found to be “AI-washing” their descriptions of business operations, claiming to have an artificial intelligence angle where one does not exist. He did not connect this issue with SPACs directly,...

by Nicholas Alan Clayton on 2023-12-11 at 7:57am

At the SPAC of Dawn This week is set to see SPACs rush to tie up business combinations nicely in a bow before the final two weeks of the year. Eight SPACs currently have completion votes on the docket this week, while there are currently just four more booked for the rest of 2023. Eight...

by Marlena Haddad on 2023-12-11 at 7:52am

SportsMap Tech Acquisition Corp. (NASDAQ:SMAP) announced this morning that its shareholders approved its business combination with intelligent thermal imaging provider Infrared Cameras Holdings (ICI) during a special meeting on December 8. A total of 3,829,673 shares of the common stock, representing approximately 73.86% of the issued and outstanding shares, were present at the meeting, constituting...

by Kristi Marvin on 2023-12-09 at 11:45am

Terms Tracker for the Week Ending December 8, 2023 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Well that escalated quickly. While last week was quiet, this week was far busier. SPACs saw one IPO start trading after pricing on Friday of...

by Marlena Haddad on 2023-12-08 at 1:59pm

Mobiv Acquisition Corp. (NASDAQ:MOBV) announced this afternoon that it has closed its combination with EV motorcycle-maker SRIVARU. Shareholders originally approved the deal at a special meeting held back on September 28, but at that time, the parties expected the transaction to take just a week to close. Redemptions whittled Mobiv’s IPO share pool of 10,005,000 down...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved